Nuformix PLC Result of AGM (2682X)
25 Août 2022 - 3:39PM
UK Regulatory
TIDMNFX
RNS Number : 2682X
Nuformix PLC
25 August 2022
Nuformix plc
Result of Annual General Meeting
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, announces that the Annual General Meeting of Nuformix
plc was held earlier today and all resolutions put to shareholders
were duly passed and approved on a show of hands at the meeting.
The results of the proxy voting position received in advance of the
meeting are reported below:
Resolution Ordinary/ For Against Total
Special votes cast
No. of % No. of %
votes votes
To receive the annual
report and accounts
for the year ended
1 31 March 2022 Ordinary 150,018,268 100 0 0 150,018,268
To approve the Remuneration
2 Policy Ordinary 149,469,749 99.86 217,007 0.14 149,686,756
To re-appoint Julian
3 Gilbert as a director Ordinary 150,096,308 99.93 106,121 0.07 150,202,429
To re-appoint s
Madeleine Kennedy
4 as a director Ordinary 150,096,308 99.93 106,121 0.07 150,202,429
To re-appoint Jeffreys
Henry Audit Limited
5 as auditor Ordinary 150,096,308 99.93 106,121 0.07 150,202,429
To authorise the
Directors to determine
6 the auditor's fees. Ordinary 149,295,087 99.40 907,342 0.60 150,202,429
To authorise the
Directors to allot
7 shares. Ordinary 146,859,280 97.78 3,331,149 2.22 150,190,429
To authorise the
Directors to disapply
8 pre-emption rights. Special 146,905,107 97.81 3,285,322 2.19 150,190,429
To authorise the
Company to purchase
9 its own shares. Special 150,139,861 99.93 112,568 0.07 150,252,429
To authorise calling
of a general meeting
on 14 clear days'
10 notice. Special 150,102,429 99.93 100,000 0.07 150,202,429
A vote withheld is not a vote in law and is not counted in the
calculation of votes validly cast for or against a resolution.
The Company's issued share capital is 709,309,368 ordinary
shares of GBP0.001 each.
Enquiries:
Nuformix plc
Dr Daniel Gooding, Executive Director Via IFC Advisory
Dr Julian Gilbert, Non-executive
Chairman
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase 1-ready assets with potential for significant value and
early licensing opportunities.
For more information, please visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGXELFLLVLXBBV
(END) Dow Jones Newswires
August 25, 2022 09:39 ET (13:39 GMT)
Nuformix (LSE:NFX)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Nuformix (LSE:NFX)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025